Возможности текстурного анализа лучевых методов визуализации в диагностике образований паренхимы почки

В настоящем обзоре изложены основные направления текстурного анализа в лечении пациентов с образованиями паренхимы почки, используемые в современной медицине. Представлены возможности применения радиомики в диагностике и лечении больных с почечно-клеточным раком.

1. Wilhelm Konrad Roentgen-The Centennial of His Birth-Semicentennial of the X-Rays. JAMA 2020;323(15):1512. DOI: 10.1001/jama.2019.13400.

2. Hounsfield G.N. Computerized transverse axial scanning (tomography): Part I. Description of system 1975. Br J Radiol 1973;68(815):H166-72.

3. Pincock S. US and UK researchers share Nobel prize. Paul C. Lauterbur and Peter Mansfield share award for seminal work on MRI. Lancet 2003;362(9391):1203. DOI: 10.1016/s0140-6736(03)14557-6.

4. Davnall F., Yip C.S.P., Ljungqvist G. et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 2012;3(6):573-89. DOI: 10.1007/s13244-012-0196-6.

5. Haralick R.M., Shanmugam K., Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern 1973;SMC-3(6):610-21. DOI: 10.1109/TSMC.1973.4309314.

6. Aerts H.J.W.L. The potential of radiomic-based phenotyping in precisionmedicine a review. JAMA Oncol 2016;2(12):1636-42. DOI: 10.1001/jamaoncol.2016.2631.

7. Lubner M.G., Smith A.D., Sandrasegaran K. et al. CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. Radiographics 2017;37(5):1483-503. DOI: 10.1148/rg.2017170056.

8. Blobel B., Ruotsalainen P., Brochhausen M. et al. Autonomous systems and artificial intelligence in healthcare transformation to 5p medicine - ethical challenges. Stud Health Technol Inform 2020;270:1089-93. DOI: 10.3233/SHTI200330.

9. DeCastro G.J., McKiernan J.M. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008;35(4):581-92. DOI: 10.1016/j.ucl.2008.07.005.

10. Frank I., Blute M.L., Cheville J.C. et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003;170(6 Pt 1):2217-20. DOI: 10.1097/01.ju.0000095475.12515.5e.

11. Zhou L., Zhang Z., Chen Y.C. et al. A deep learning-based radiomics model for differentiating benign and malignant renal tumors. Transl Oncol 2019;12(2):292-300. DOI: 10.1016/j.tranon.2018.10.012.

12. Said D., Hectors S.J., Wilck E. et al. Characterization of solid renal neoplasms using MRI-based quantitative radiomics features. Abdom Radiol 2020;45(9):2840-50. DOI: 10.1007/s00261-020-02540-4.

13. Uhlig J., Biggemann L., Nietert M.M. et al. Discriminating malignant and benign clinical T1 renal masses on computed tomography: a pragmatic radiomics and machine learning approach. Medicine 2020;99(16):e19725. DOI: 10.1097/MD.0000000000019725.

14. Yap F.Y., Varghese B.A., Cen S.Y. et al. Shape and texture-based radiomics signature on CT effectively discriminates benign from malignant renal masses. Eur Radiol 2021;31(2):1011-21. DOI: 10.1007/s00330-020-07158-0.

15. Deng Y., Soule E., Samuel A. et al. CT texture analysis in the differentiation of major renal cell carcinoma subtypes and correlation with Fuhrman grade. Eur Radiol 2019;29(12):6922-9. DOI: 10.1007/s00330-019-06260-2.

16. Erdim C., Yardimci A.H., Bektas C.T. et al. Prediction of benign and malignant solid renal masses: machine learning-based CT texture analysis. Acad Radiol 2020;27(10):1422-9. DOI: 10.1016/j.acra.2019.12.015.

17. Xi I.L., Zhao Y., Wang R. et al. Deep learning to distinguish benign from malignant renal lesions based on routine MR imaging. Clin Cancer Res 2020;26(8):1944-52. DOI: 10.1158/1078-0432.CCR-19-0374.

18. Znaor A., Lortet-Tieulent J., Laversanne M. et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 2015;67(3):519-30. DOI: 10.1016/j.eururo.2014.10.002.

19. Cheville J.C., Lohse C.M., Zincke H. et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27(5):612-24. DOI: 10.1097/00000478-200305000-00005.

20. Yu H.S., Scalera J., Khalid M. et al. Texture analysis as a radiomic marker for differentiating renal tumors. Abdom Radiol 2017;42(10):2470-8. DOI: 10.1007/s00261-017-1144-1.

21. Zhang G.M.Y., Shi B., Xue H.D. et al. Can quantitative CT texture analysis be used to differentiate subtypes of renal cell carcinoma? Clin Radiol 2019;74(4):287-94. DOI: 10.1016/j.crad.2018.11.009.

22. Duan C., Li N., Niu L. et al. CT texture analysis for the differentiation of papillary renal cell carcinoma subtypes. Abdom Radiol 2020;45(11):3860-8. DOI: 10.1007/s00261-020-02588-2.

23. Wang W., Cao K.M., Jin S.M. et al. Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis. Eur Radiol 2020;30(10):5738—47. DOI: 10.1007/s00330-020-06896-5.

24. Fuhrman S., Lasky L.C., Limas C. Prognostic significance of morphologic parametrs in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-63. DOI: 10.1097/00000478-198210000-00007.

25. Moch H., Cubilla A.L., Humphrey P.A. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs — part A: renal, penile, and testicular tumours. Eur Urol 2016;70(1):93-105. DOI: 10.1016/j.eururo.2016.02.029.

26. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090-5. DOI: 10.1016/S0022-5347(05)67699-9.

27. Feng Z., Shen Q., Li Y., Hu Z. CT texture analysis: a potential tool for predicting the Fuhrman grade of clear-cell renal carcinoma. Cancer Imaging 2019;19(1):6. DOI: 10.1186/s40644-019-0195-7.

28. Goyal A., Razik A., Kandasamy D. et al. Role of MR texture analysis in histological subtyping and grading of renal cell carcinoma: a preliminary study. Abdom Radiol 2019;44(10):3336-49. DOI: 10.1007/s00261-019-02122-z.

29. Boos J., Revah G., Brook O.R. et al. CT intensity distribution curve (Histogram) analysis of patients undergoing antiangiogenic therapy for metastatic renal cell carcinoma. Am J Roentgenol 2017;209(2):W85-92. DOI: 10.2214/AJR.16.17651.

30. Bharwani N., Miquel M.E., Powles T. et al. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer 2014;110(3):616-24. DOI: 10.1038/bjc.2013.790.

31. Ueno D., Yao M., Tateishi U. et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012;12:162. DOI: 10.1186/1471-2407-12-162.

32. Antunes J., Viswanath S., Rusu M. et al. Radiomics analysis on FLT-PET/MRI for characterization of early treatment response in renal cell carcinoma: a proof-of-concept study. Transl Oncol 2016;9(2):155-62. DOI: 10.1016/j.tranon.2016.01.008.

33. Goh V., Ganeshan B., Nathan P. et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011;261(1):165-71. DOI: 10.1148/radiol.11110264.